Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-101 (IL13Ra2-targeted CAR T-cells) to Treat Astrocytomas and Glioblastoma

Stock Information for Compugen Ltd.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Compugen Ltd.

Fortress Biotech Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
Journey Medical Corporation Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
Journey Medical Corporation to Ring Nasdaq Stock Market Closing Bell on August 11
Journey Medical Corporation to Announce Second Quarter 2025 Financial Results on August 12, 2025
Journey Medical Corporation Announces Expanded Payer Coverage for Emrosi(TM)
Journey Medical to Join Russell 2000® and Russell 3000® Indexes
Journey Medical Corporation Announces Emrosi(TM) Data Analysis to be Presented at the Society of Dermatology Physician Associates (SDPA) 2025 Annual Summer Dermatology Conference
Journey Medical Corporation Announces Emrosi(TM) Featured on "The Balancing Act" Airing on Lifetime TV

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.